Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment
© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Treatment with immune checkpoint inhibitors frequently leads to immune-related adverse events (irAEs). As pa...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) Editorial |
| Language: | English |
| Published: |
6 March 2016
|
| In: |
Annals of oncology
Year: 2016, Volume: 27, Issue: 7, Pages: 1353-1354 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdw128 |
| Online Access: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1093/annonc/mdw128 Verlag, kostenfrei, Volltext: https://academic.oup.com/annonc/article/27/7/1353/1741159 
|
| Author Notes: | C. Bender, A. Dimitrakopoulou-Strauss, A. Enk and J.C. Hassel |
| Summary: | © The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Treatment with immune checkpoint inhibitors frequently leads to immune-related adverse events (irAEs). As patients who have previously experienced high-grade AEs with ipilimumab are excluded from most studies with anti-programmed cell death-1 or anti-programmed cell death ligand-1 antibodies (Abs), there are little data on the safety of sequential therapy in this patient population [2, 3]. However, especially BRAF wild-type melanoma patients are in need of further treatment options after progression with ipilimumab. Hence, we treated patients who had to stop ipilimumab treatment because of a severe autoimmune reaction after complete resolution of symptoms and cessation of the immunosuppressive treatment with the anti-PD-1 Ab pembrolizumab....Data from patients treated with pembrolizumab 2 mg/kg q3w was retrospectively analyzed. Eight of 49 (16.3%) patients had... |
|---|---|
| Item Description: | Gesehen am 18.01.2018 |
| Physical Description: | Online Resource |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdw128 |